Silence Therapeutics plc Files Form 8-K: Key Updates on Tax Status and Material Agreements
London, May 18, 2026 – Silence Therapeutics plc (NASDAQ: SLN) has filed a Form 8-K with the U.S. Securities and Exchange Commission, providing shareholders and investors with several important updates. Below, we break down the key points from the filing, highlighting matters that may impact investor outlook and potentially affect share valuation.
1. Update on Passive Foreign Investment Company (PFIC) Status
Significant Tax Status Update: The company has revised its prior disclosures regarding its classification as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes. Following further tax analysis, Silence Therapeutics now believes it should not have been classified as a PFIC for its taxable year ended December 31, 2025.
- Background: A PFIC classification can have adverse U.S. federal income tax consequences for U.S. holders of the company’s securities, affecting how gains are taxed and potentially imposing additional reporting requirements.
- Shareholder Impact: The company’s updated belief that it was not a PFIC for 2025 is a positive development for U.S. investors, as it removes the risk of certain punitive tax treatments for the previous year. However, the company notes it may not provide the necessary tax information for shareholders to make a Qualified Electing Fund (QEF) election in the future, should PFIC status apply again.
Risk Factor Disclosure: Silence Therapeutics emphasizes that if it were to be classified as a PFIC in the future, there could be adverse tax consequences for U.S. holders, and encourages investors to consult their own tax advisors for specific guidance.
2. Termination of Prior Sales Agreement
Material Agreement Termination: The company has reported the termination of a prior material definitive agreement (the “Prior Sales Agreement”). This termination is referenced in Item 1.02 of the 8-K and is incorporated by reference from Item 1.01. The specifics of the terminated agreement are not detailed in the 8-K, but such events are typically considered material and may have implications for future capital-raising activities or partnerships.
3. Legal Opinion Filed
Silence Therapeutics has filed a legal opinion from Cooley (UK) LLP as Exhibit 5.1 to the Form 8-K, relating to the validity of its American Depositary Shares (ADSs). This legal opinion is standard for offerings or updates involving ADSs and assures investors regarding the legal standing of the company’s securities.
4. Current Securities Information
- Trading Symbol: SLN
- Listed Exchange: The Nasdaq Stock Market LLC
-
Securities Registered:
- American Depositary Shares (ADSs), each representing three ordinary shares, nominal value £0.05 per share
- Ordinary shares, nominal value £0.05 per share (not for trading, but only in connection with ADS listing)
5. Emerging Growth Company Status
The filing explicitly states that Silence Therapeutics is not an emerging growth company under U.S. securities law definitions. Therefore, it is not eligible for certain reduced compliance or reporting requirements.
6. Forward-Looking Statements and Risk Factors
The 8-K includes a standard cautionary note regarding forward-looking statements, emphasizing that expectations regarding PFIC status and other disclosures are subject to uncertainties and risks. Actual results could differ materially from these statements due to a range of factors, including financial, market, and regulatory developments.
Potential Share Price Impact
- Tax Status Clarity: The clarification that Silence Therapeutics was not a PFIC for the year ended December 31, 2025 may be viewed positively by U.S. investors, as it removes a potential overhang of adverse tax treatment for the previous year’s holdings.
- Agreement Termination: The end of a material agreement could be interpreted in several ways, depending on the nature and context (not detailed in the 8-K), and investors should monitor for future disclosures regarding new arrangements or capital markets activity.
Other Notable Points
- No Trading Symbol for Ordinary Shares: Ordinary shares are not for trading in the U.S., but are listed only in connection with the ADSs.
- Compliance: The company continues to comply with all U.S. securities regulations and reporting standards.
Disclaimer: This article is for informational purposes only and does not constitute investment, tax, or legal advice. Investors are encouraged to consult their own advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ. The information presented is based on the company’s public SEC filings as of May 18, 2026.
